Year: 2014
Type: article
Abstract: // Catherine Wilson 1 , Katrina Nicholes 2 , Daisy Bustos 2 , Eva Lin 1 , Qinghua Song 3 , Jean-Philippe Stephan 2 , Donald S. Kirkpatrick 2 and Jeff Settleman 1 1 Department of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, CA 2 Department of Discovery Protein Chemistry, Genentech, 1 DNA Way, South San Francisco, CA 3 Department of Discovery Nonclinical Biostatistics, Genentech, 1 DNA Way, South San Francisco, CA Correspondence: Jeff Settleman, email: // Keywords : EMT, Src, drug resistance, dasatinib, cancer Received : July 19, 2014 Accepted : August 26, 2014 Published : August 27, 2014 Abstract Epithelial to mesenchymal transition (EMT) is a key process in embryonic development and has been associated with cancer metastasis and drug resistance. For example, in EGFR mutated non-small cell lung cancers (NSCLC), EMT has been associated with acquired resistance to the EGFR inhibitor erlotinib. Moreover, “EGFR-addicted” cancer cell lines induced to undergo EMT become erlotinib-resistant in vitro . To identify potential therapeutic vulnerabilities specifically within these mesenchymal, erlotinib-resistant cells, we performed a small molecule screen of ~200 established anti-cancer agents using the EGFR mutant NSCLC HCC827 cell line and a corresponding mesenchymal derivative line. The mesenchymal cells were more resistant to most tested agents; however, a small number of agents showed selective growth inhibitory activity against the mesenchymal cells, with the most potent being the Abl/Src inhibitor, dasatinib. Analysis of the tyrosine phospho-proteome revealed several Src/FAK pathway kinases that were differentially phosphorylated in the mesenchymal cells, and RNAi depletion of the core Src/FAK pathway components in these mesenchymal cells caused apoptosis. These findings reveal a novel role for Src/FAK pathway kinases in drug resistance and identify dasatinib as a potential therapeutic for treatment of erlotinib resistance associated with EMT.
Source: Oncotarget
Institution: Genentech
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funder: Genentech
OpenAlex ID: W2133555426
